BioCryst (BCRX) Pharmaceuticals announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired employees restricted stock units covering an aggregate of 47,250 shares of BioCryst common stock. The RSUs were granted as of June 2, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst highlights real-world data on ORLADEYO in HAE attacks
- BioCryst presents new real-world evidence on ORLADEYO in severe HAE
- BioCryst’s Strategic Advancements and Market Potential: A Buy Rating by Serge Belanger
- BioCryst’s ORLADEYO Receives FDA Priority Review
- BioCryst announces FDA acceptance of NDA for ORLADEYO
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue